Center for InVivo Imaging and Therapy Shared Resources Core

项目摘要/摘要-活体成像和治疗中心 体内成像和治疗中心(Civit)是由SJCCC管理的与 提供尖端成像和图像引导治疗技术以推动 临床前癌症模型研究。作为SJCCC战略计划的一部分，HMP、DBSTP、NBTP和CBP 将增强的动物建模作为其临床前研究工作的中心要求， Civit是这些计划的核心。Civit在推动SJCCC临床前研究方面发挥了重要作用，通过提供 领先的外科和成像专业知识，使计划成员能够轻松地建模和调查遗传和 脑瘤、实体瘤和白血病的原位移植模型。Civit与SJCCC成员合作 在建模和进行临床前实验方面提供咨询和技术专业知识 研究。CORE还提供研讨会，教育用户有关新的临床前成像应用和 技术。Civit由NCI R50资助的兽医和生物医学工程师沃尔特·阿克斯博士执导 在癌症成像和治疗研究方面拥有超过11年的经验。他得到了1名员工的支持 科学家和6名高技能研究技术人员，提供成像、手术和治疗服务，以及 与SJCCC小组合作计划和执行实验，以确保动物研究在 最高标准。Civit对项目癌症研究的影响从高水平得到了证明 在《血液》(n=5)等影响较大的期刊上发表合作出版物和重要科学投稿的水平； 自然遗传学(n=3)和癌细胞(n=6)。在本供资期间，自1月起共出版了66份出版物 2013-2017年12月使用Civit，占28个(42%)计划间和33个(50%) 方案内协作。这些出版物来自5个方案中的4个：DBSTP(n=16)、HMP CBP组34例，NBTP组25例。在指数年(2017财年)，94%的调查人员使用Civit 均为SJCCC成员(49/52)。下一阶段的目标包括升级高频超声波(Vevo 3100，Visualsonics)为图像引导注射和肿瘤体积提供最先进的能力 测量；获得能够荧光的手术显微镜以优化脑干O-PDX植入 和图像引导切除O-PDX小鼠肿瘤；以及升级具有BLI功能的IGRT系统 (Muriglo，Xstrahl)为临床前试验启用肿瘤选择性辐射。这些先进的技术将 确保继续为SJCCC项目的临床前研究提供高水平的支持。

PROJECT SUMMARY/ABSTRACT— Center for In Vivo Imaging and Therapeutics The Center for In Vivo Imaging and Therapeutics (CIVIT) is an SJCCC-managed Shared Resource with the overarching goal of providing cutting-edge imaging and image-guided therapy technologies to advance preclinical cancer modeling research. As part of the SJCCC Strategic Plan, the HMP, DBSTP, NBTP, and CBP prioritized enhanced animal modeling as a central requirement for their preclinical research endeavors, with CIVIT at the center of these plans. CIVIT plays a major role in advancing SJCCC preclinical research by offering leading surgical and imaging expertise, allowing Program members to readily model and survey genetic and orthotopic-implant models of brain tumors, solid tumors, and leukemias. CIVIT partners with SJCCC members to provide consultative and technical expertise in modeling and conducting experiments for their preclinical research. The core also offers seminars to educate users about new preclinical imaging applications and technologies. CIVIT is directed by Dr. Walter Akers, an NCI R50-funded veterinarian and biomedical engineer with more than 11 years of experience in cancer imaging and therapy research. He is supported by 1 staff scientist and 6 highly skilled research technologists to provide imaging, surgery, and therapeutic services, and partner with SJCCC groups in planning and performing experiments to ensure animal studies are conducted at the highest standard. The impact of the CIVIT on the cancer research of the Programs is evidenced by the high level of collaborative publications and key scientific contributions in high-impact journals such as Blood (n=5), Nature Genetics (n=3), and Cancer Cell (n=6). During the current funding period, 66 publications from January 2013–December 2017 used the CIVIT, representing 28 (42%) interprogrammatic and 33 (50%) intraprogrammatic collaborations. These included publications from 4 of the 5 Programs: DBSTP (n=16), HMP (n=25), CBP (n=34), and NBTP (n=25). During the index year (FY2017), 94% of all investigators using the CIVIT were SJCCC members (49/52). Goals for the next period include upgrading high-frequency ultrasounds (Vevo 3100, Visualsonics) to provide state-of-the-art capabilities for image-guided injections and tumor volume measurement; obtaining a fluorescence-capable surgical microscope to optimize brainstem O-PDX implantation and image-guided resections of O-PDX tumors in mice; and upgrading the IGRT system with BLI capability (Muriglo, Xstrahl) to enable tumor-selective radiation for preclinical trials. These advanced technologies will ensure continued high-level support of the preclinical research of the SJCCC Programs.